GENETIC VARIABILITY TO GLP1 TREATMENT

What this study is testing ClinicalTrials.gov NCT06298799 ↗

Description as written by the study sponsor.

The goal of this retrospective study is to assess whether a selection of genetic variants may allow us to identify individuals who will have a satisfactory response after GLP-1 treatment in terms of weight loss, sugar level reduction, and adverse events. Participants will The study consists of a single visit at the diabetes unit clinic at the involved study sites. The following will be performed for every subject at the study screening enrollment visit: * Informed consent * Study eligibility (Inclusion / Exclusion criteria) * Collection of demographic data (age (date of birth), gender, ethnic origin) * General and T2DM medical history review (per subject file) * Concomitant medication review (at enrollment) * Physical attributes (Body Weight, Height, BMI) * Allocation to study cohort and study subgroup * Saliva and blood collection for genetic tests * Self-reported questionnaire for Ozempic (Semaglutide) experience

Treatments tested

• DNA Sequencing and Analysis Genetic

  DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.

• differential expression analysis with RNA-sequencing (RNA seq) experiments Genetic

  Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules